{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:45:14Z","timestamp":1793904314027,"version":"4.8.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,15]],"date-time":"2018-08-15T00:00:00Z","timestamp":1534291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,8,15]],"date-time":"2018-08-15T00:00:00Z","timestamp":1534291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Chicago Biomedical Consortium Postdoctoral Award PDR-061"},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA210904"],"award-info":[{"award-number":["CA210904"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA180813"],"award-info":[{"award-number":["CA180813"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Primary effusion lymphoma (PEL) is caused by Kaposi\u2019s sarcoma-associated herpesvirus. Our understanding of PEL is poor and therefore treatment strategies are lacking. To address this need, we conducted genome-wide CRISPR\/Cas9 knockout screens in eight PEL cell lines. Integration with data from unrelated cancers identifies 210 genes as PEL-specific oncogenic dependencies. Genetic requirements of PEL cell lines are largely independent of Epstein-Barr virus co-infection. Genes of the NF-\u03baB pathway are individually non-essential. Instead, we demonstrate requirements for IRF4 and MDM2. PEL cell lines depend on cellular cyclin D2 and c-FLIP despite expression of viral homologs. Moreover, PEL cell lines are addicted to high levels of MCL1 expression, which are also evident in PEL tumors. Strong dependencies on cyclin D2 and MCL1 render PEL cell lines highly sensitive to palbociclib and S63845. In summary, this work comprehensively identifies genetic dependencies in PEL cell lines and identifies novel strategies for therapeutic intervention.<\/jats:p>","DOI":"10.1038\/s41467-018-05506-9","type":"journal-article","created":{"date-parts":[[2018,8,9]],"date-time":"2018-08-09T09:32:29Z","timestamp":1533807149000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Gene essentiality landscape and druggable oncogenic dependencies in herpesviral primary effusion lymphoma"],"prefix":"10.1038","volume":"9","author":[{"given":"Mark","family":"Manzano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajinkya","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Waldrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep S.","family":"Dave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Behdad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Gottwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,15]]},"reference":[{"key":"5506_CR1","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood.V88.2.645.bloodjournal882645","volume":"88","author":"RG Nador","year":"1996","unstructured":"Nador, R. G. et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi\u2019s sarcoma-associated herpes virus. Blood 88, 645\u2013656 (1996).","journal-title":"Blood"},{"key":"5506_CR2","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1056\/NEJM199505043321802","volume":"332","author":"E Cesarman","year":"1995","unstructured":"Cesarman, E., Chang, Y., Moore, P. S., Said, J. W. & Knowles, D. M. Kaposi\u2019s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N. Engl. J. Med. 332, 1186\u20131191 (1995).","journal-title":"N. Engl. J. Med."},{"key":"5506_CR3","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1126\/science.7997879","volume":"266","author":"Y Chang","year":"1994","unstructured":"Chang, Y. et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi\u2019s sarcoma. Science 266, 1865\u20131869 (1994).","journal-title":"Science"},{"key":"5506_CR4","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1182\/blood.V86.4.1276.bloodjournal8641276","volume":"86","author":"J Soulier","year":"1995","unstructured":"Soulier, J. et al. Kaposi\u2019s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman\u2019s disease. Blood 86, 1276\u20131280 (1995).","journal-title":"Blood"},{"key":"5506_CR5","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1146\/annurev-pathol-012513-104656","volume":"9","author":"E Cesarman","year":"2014","unstructured":"Cesarman, E. Gammaherpesviruses and lymphoproliferative disorders. Annu. Rev. Pathol. 9, 349\u2013372 (2014).","journal-title":"Annu. Rev. Pathol."},{"key":"5506_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.5582\/irdr.2014.01010","volume":"3","author":"S Okada","year":"2014","unstructured":"Okada, S., Goto, H. & Yotsumoto, M. Current status of treatment for primary effusion lymphoma. Intractable Rare Dis. Res. 3, 65\u201374 (2014).","journal-title":"Intractable Rare Dis. Res."},{"key":"5506_CR7","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1200\/JCO.2005.07.084","volume":"23","author":"E Boulanger","year":"2005","unstructured":"Boulanger, E. et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J. Clin. Oncol. 23, 4372\u20134380 (2005).","journal-title":"J. Clin. Oncol."},{"key":"5506_CR8","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1002\/1097-0142(20011215)92:12<3076::AID-CNCR10117>3.0.CO;2-D","volume":"92","author":"H Katano","year":"2001","unstructured":"Katano, H., Sato, Y. & Sata, T. Expression of p53 and human herpesvirus-8 (HHV-8)-encoded latency-associated nuclear antigen with inhibition of apoptosis in HHV-8-associated malignancies. Cancer 92, 3076\u20133084 (2001).","journal-title":"Cancer"},{"key":"5506_CR9","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1128\/JVI.01757-06","volume":"81","author":"CE Petre","year":"2007","unstructured":"Petre, C. E., Sin, S. H. & Dittmer, D. P. Functional p53 signaling in Kaposi\u2019s sarcoma-associated herpesvirus lymphomas: implications for therapy. J. Virol. 81, 1912\u20131922 (2007).","journal-title":"J. Virol."},{"key":"5506_CR10","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1182\/blood.V86.7.2708.2708","volume":"86","author":"E Cesarman","year":"1995","unstructured":"Cesarman, E. et al. In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi\u2019s sarcoma-associated herpesvirus-like (KSHV) DNA sequences. Blood 86, 2708\u20132714 (1995).","journal-title":"Blood"},{"key":"5506_CR11","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1182\/blood-2003-05-1710","volume":"103","author":"P Trivedi","year":"2004","unstructured":"Trivedi, P. et al. Infection of HHV-8+ primary effusion lymphoma cells with a recombinant Epstein-Barr virus leads to restricted EBV latency, altered phenotype, and increased tumorigenicity without affecting TCL1 expression. Blood 103, 313\u2013316 (2004).","journal-title":"Blood"},{"key":"5506_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.chom.2017.06.009","volume":"22","author":"D McHugh","year":"2017","unstructured":"McHugh, D. et al. Persistent KSHV infection increases EBV-associated tumor formation in vivo via enhanced EBV lytic gene expression. Cell Host Microbe 22, 61\u201373 (2017).\u00a0","journal-title":"Cell Host Microbe"},{"key":"5506_CR13","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1182\/blood-2004-08-3052","volume":"105","author":"A Godfrey","year":"2005","unstructured":"Godfrey, A., Anderson, J., Papanastasiou, A., Takeuchi, Y. & Boshoff, C. Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA. Blood 105, 2510\u20132518 (2005).","journal-title":"Blood"},{"key":"5506_CR14","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1084\/jem.20031467","volume":"199","author":"I Guasparri","year":"2004","unstructured":"Guasparri, I., Keller, S. A. & Cesarman, E. KSHV vFLIP is essential for the survival of infected lymphoma cells. J. Exp. Med. 199, 993\u20131003 (2004).","journal-title":"J. Exp. Med."},{"key":"5506_CR15","doi-asserted-by":"crossref","unstructured":"Wies, E. et al.\u00a0The viral interferon-regulatory factor-3 is required for the survival of KSHV-infected primary effusion lymphoma cells. Blood 111, 320\u2013327 (2008).\u00a0\u00a0","DOI":"10.1182\/blood-2007-05-092288"},{"key":"5506_CR16","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1128\/JVI.01321-09","volume":"84","author":"W Chen","year":"2010","unstructured":"Chen, W., Hilton, I. B., Staudt, M. R., Burd, C. E. & Dittmer, D. P. Distinct p53, p53:LANA, and LANA complexes in Kaposi\u2019s sarcoma-associated herpesvirus lymphomas. J. Virol. 84, 3898\u20133908 (2010).","journal-title":"J. Virol."},{"key":"5506_CR17","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1172\/JCI30945","volume":"117","author":"G Sarek","year":"2007","unstructured":"Sarek, G. et al. Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas. J. Clin. Invest. 117, 1019\u20131028 (2007).","journal-title":"J. Clin. Invest."},{"key":"5506_CR18","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1038\/onc.2012.385","volume":"32","author":"S Santag","year":"2013","unstructured":"Santag, S. et al. Recruitment of the tumour suppressor protein p73 by Kaposi\u2019s Sarcoma Herpesvirus latent nuclear antigen contributes to the survival of primary effusion lymphoma cells. Oncogene 32, 3676\u20133685 (2013).","journal-title":"Oncogene"},{"key":"5506_CR19","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1128\/JVI.75.1.429-438.2001","volume":"75","author":"C Rivas","year":"2001","unstructured":"Rivas, C., Thlick, A. E., Parravicini, C., Moore, P. S. & Chang, Y. Kaposi\u2019s sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. J. Virol. 75, 429\u2013438 (2001).","journal-title":"J. Virol."},{"key":"5506_CR20","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1182\/blood.V96.7.2537.h8002537_2537_2542","volume":"96","author":"SA Keller","year":"2000","unstructured":"Keller, S. A., Schattner, E. J. & Cesarman, E. Inhibition of NF-kappa B induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 96, 2537\u20132542 (2000).","journal-title":"Blood"},{"key":"5506_CR21","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.1242\/jcs.00691","volume":"116","author":"N Field","year":"2003","unstructured":"Field, N. et al. KSHV vFLIP binds to IKK-gamma to activate IKK. J. Cell Sci. 116, 3721\u20133728 (2003).","journal-title":"J. Cell Sci."},{"key":"5506_CR22","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/386517a0","volume":"386","author":"M Thome","year":"1997","unstructured":"Thome, M. et al. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386, 517\u2013521 (1997).","journal-title":"Nature"},{"key":"5506_CR23","doi-asserted-by":"publisher","first-page":"5738","DOI":"10.1038\/sj.onc.1202976","volume":"18","author":"PM Chaudhary","year":"1999","unstructured":"Chaudhary, P. M., Jasmin, A., Eby, M. T. & Hood, L. Modulation of the NF-kappa B pathway by virally encoded death effector domains-containing proteins. Oncogene 18, 5738\u20135746 (1999).","journal-title":"Oncogene"},{"key":"5506_CR24","doi-asserted-by":"publisher","first-page":"6345","DOI":"10.1128\/JVI.00028-14","volume":"88","author":"B Tolani","year":"2014","unstructured":"Tolani, B., Matta, H., Gopalakrishnan, R., Punj, V. & Chaudhary, P. M. NEMO is essential for Kaposi\u2019s sarcoma-associated herpesvirus-encoded vFLIP K13-induced gene expression and protection against death receptor-induced cell death, and its N-terminal 251 residues are sufficient for this process. J. Virol. 88, 6345\u20136354 (2014).","journal-title":"J. Virol."},{"key":"5506_CR25","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/978-3-642-38965-8_13","volume":"193","author":"E Cousins","year":"2014","unstructured":"Cousins, E. & Nicholas, J. Molecular biology of human herpesvirus 8: novel functions and virus-host interactions implicated in viral pathogenesis and replication. Recent Results Cancer Res. 193, 227\u2013268 (2014).","journal-title":"Recent Results Cancer Res."},{"key":"5506_CR26","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1182\/blood-2006-06-028092","volume":"109","author":"SH Sin","year":"2007","unstructured":"Sin, S. H. et al. Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood 109, 2165\u20132173 (2007).","journal-title":"Blood"},{"key":"5506_CR27","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1158\/1078-0432.CCR-04-1857","volume":"11","author":"S Uddin","year":"2005","unstructured":"Uddin, S. et al. Inhibition of phosphatidylinositol 3\u2019-kinase\/AKT signaling promotes apoptosis of primary effusion lymphoma cells. Clin. Cancer Res. 11, 3102\u20133108 (2005).","journal-title":"Clin. Cancer Res."},{"key":"5506_CR28","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1128\/jvi.71.3.1984-1991.1997","volume":"71","author":"M Li","year":"1997","unstructured":"Li, M. et al. Kaposi\u2019s sarcoma-associated herpesvirus encodes a functional cyclin. J. Virol. 71, 1984\u20131991 (1997).","journal-title":"J. Virol."},{"key":"5506_CR29","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/36606","volume":"390","author":"C Swanton","year":"1997","unstructured":"Swanton, C. et al. Herpes viral cyclin\/Cdk6 complexes evade inhibition by CDK inhibitor proteins. Nature 390, 184\u2013187 (1997).","journal-title":"Nature"},{"key":"5506_CR30","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1128\/JVI.79.2.1244-1251.2005","volume":"79","author":"W Fan","year":"2005","unstructured":"Fan, W. et al. Distinct subsets of primary effusion lymphoma can be identified based on their cellular gene expression profile and viral association. J. Virol. 79, 1244\u20131251 (2005).","journal-title":"J. Virol."},{"key":"5506_CR31","doi-asserted-by":"publisher","first-page":"10399","DOI":"10.1073\/pnas.1630810100","volume":"100","author":"RG Jenner","year":"2003","unstructured":"Jenner, R. G. et al. Kaposi\u2019s sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile. Proc. Natl Acad. Sci. USA 100, 10399\u201310404 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"5506_CR32","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.1182\/blood-2002-10-3090","volume":"101","author":"U Klein","year":"2003","unstructured":"Klein, U. et al. Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood 101, 4115\u20134121 (2003).","journal-title":"Blood"},{"key":"5506_CR33","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature07064","volume":"454","author":"AL Shaffer","year":"2008","unstructured":"Shaffer, A. L. et al. IRF4 addiction in multiple myeloma. Nature 454, 226\u2013231 (2008).","journal-title":"Nature"},{"key":"5506_CR34","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/onc.2015.245","volume":"35","author":"R Gopalakrishnan","year":"2016","unstructured":"Gopalakrishnan, R., Matta, H., Tolani, B., Triche, T. Jr. & Chaudhary, P. M. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors. Oncogene 35, 1797\u20131810 (2016).","journal-title":"Oncogene"},{"key":"5506_CR35","doi-asserted-by":"publisher","first-page":"1258096","DOI":"10.1126\/science.1258096","volume":"346","author":"JA Doudna","year":"2014","unstructured":"Doudna, J. A. & Charpentier, E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 346, 1258096 (2014).","journal-title":"Science"},{"key":"5506_CR36","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrg3899","volume":"16","author":"O Shalem","year":"2015","unstructured":"Shalem, O., Sanjana, N. E. & Zhang, F. High-throughput functional genomics using CRISPR-Cas9. Nat. Rev. Genet. 16, 299\u2013311 (2015).","journal-title":"Nat. Rev. Genet."},{"key":"5506_CR37","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","volume":"34","author":"JG Doench","year":"2016","unstructured":"Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat. Biotechnol. 34, 184\u2013191 (2016).","journal-title":"Nat. Biotechnol."},{"key":"5506_CR38","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nmeth.3047","volume":"11","author":"NE Sanjana","year":"2014","unstructured":"Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783\u2013784 (2014).","journal-title":"Nat. Methods"},{"key":"5506_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-015-0843-6","volume":"16","author":"W Li","year":"2015","unstructured":"Li, W. et al. Quality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR. Genome Biol. 16, 281 (2015).","journal-title":"Genome Biol."},{"key":"5506_CR40","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1158\/2159-8290.CD-16-0154","volume":"6","author":"AJ Aguirre","year":"2016","unstructured":"Aguirre, A. J. et al. Genomic copy number dictates a gene-independent cell response to CRISPR\/Cas9 targeting. Cancer Discov. 6, 914\u2013929 (2016).","journal-title":"Cancer Discov."},{"key":"5506_CR41","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.chom.2017.04.005","volume":"21","author":"Y Ma","year":"2017","unstructured":"Ma, Y. et al. CRISPR\/Cas9 screens reveal Epstein-Barr virus-transformed B cell host dependency factors. Cell Host Microbe 21, 580\u2013591 (2017).\u00a0","journal-title":"Cell Host Microbe"},{"key":"5506_CR42","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1126\/science.aac7041","volume":"350","author":"T Wang","year":"2015","unstructured":"Wang, T. et al. Identification and characterization of essential genes in the human genome. Science 350, 1096\u20131101 (2015).","journal-title":"Science"},{"key":"5506_CR43","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.cell.2017.01.013","volume":"168","author":"T Wang","year":"2017","unstructured":"Wang, T. et al. Gene essentiality profiling reveals gene networks and synthetic lethal interactions with oncogenic Ras. Cell 168, 890\u2013903 (2017).\u00a0","journal-title":"Cell"},{"key":"5506_CR44","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"5506_CR45","doi-asserted-by":"publisher","first-page":"5739","DOI":"10.1128\/JVI.00236-15","volume":"89","author":"O Cojohari","year":"2015","unstructured":"Cojohari, O. et al. BH3 profiling reveals selectivity by herpesviruses for specific Bcl-2 proteins to mediate survival of latently infected cells. J. Virol. 89, 5739\u20135746 (2015).","journal-title":"J. Virol."},{"key":"5506_CR46","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1182\/blood-2013-01-479972","volume":"122","author":"U Nayar","year":"2013","unstructured":"Nayar, U. et al. Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies. Blood 122, 2837\u20132847 (2013).","journal-title":"Blood"},{"key":"5506_CR47","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.coviro.2016.06.012","volume":"19","author":"M Lagunoff","year":"2016","unstructured":"Lagunoff, M. Activation of cellular metabolism during latent Kaposi\u2019s sarcoma herpesvirus infection. Curr. Opin. Virol. 19, 45\u201349 (2016).","journal-title":"Curr. Opin. Virol."},{"key":"5506_CR48","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.cell.2015.11.015","volume":"163","author":"T Hart","year":"2015","unstructured":"Hart, T. et al. High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. Cell 163, 1515\u20131526 (2015).","journal-title":"Cell"},{"key":"5506_CR49","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1126\/science.1246981","volume":"343","author":"T Wang","year":"2014","unstructured":"Wang, T., Wei, J. J., Sabatini, D. M. & Lander, E. S. Genetic screens in human cells using the CRISPR-Cas9 system. Science 343, 80\u201384 (2014).","journal-title":"Science"},{"key":"5506_CR50","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood.V88.2.674.bloodjournal882674","volume":"88","author":"M Chesi","year":"1996","unstructured":"Chesi, M. et al. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood 88, 674\u2013681 (1996).","journal-title":"Blood"},{"key":"5506_CR51","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1101\/gad.276725.115","volume":"30","author":"KL O\u2019Neill","year":"2016","unstructured":"O\u2019Neill, K. L., Huang, K., Zhang, J., Chen, Y. & Luo, X. Inactivation of prosurvival Bcl-2 proteins activates Bax\/Bak through the outer mitochondrial membrane. Genes Dev. 30, 973\u2013988 (2016).","journal-title":"Genes Dev."},{"key":"5506_CR52","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nature08822","volume":"463","author":"R Beroukhim","year":"2010","unstructured":"Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899\u2013905 (2010).","journal-title":"Nature"},{"key":"5506_CR53","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature19830","volume":"538","author":"A Kotschy","year":"2016","unstructured":"Kotschy, A. et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature 538, 477\u2013482 (2016).","journal-title":"Nature"},{"key":"5506_CR54","first-page":"1309","volume":"146","author":"S Krajewski","year":"1995","unstructured":"Krajewski, S. et al. Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. Am. J. Pathol. 146, 1309\u20131319 (1995).","journal-title":"Am. J. Pathol."},{"key":"5506_CR55","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1182\/blood-2005-07-2730","volume":"107","author":"SA Keller","year":"2006","unstructured":"Keller, S. A. et al. NF-kappaB is essential for the progression of KSHV- and EBV-infected lymphomas in vivo. Blood 107, 3295\u20133302 (2006).","journal-title":"Blood"},{"key":"5506_CR56","doi-asserted-by":"publisher","first-page":"e59292","DOI":"10.1371\/journal.pone.0059292","volume":"8","author":"H Rauert-Wunderlich","year":"2013","unstructured":"Rauert-Wunderlich, H. et al. The IKK inhibitor Bay 11-7082 induces cell death independent from inhibition of activation of NFkappaB transcription factors. PLoS ONE 8, e59292 (2013).","journal-title":"PLoS ONE"},{"key":"5506_CR57","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.canlet.2008.03.045","volume":"268","author":"DE White","year":"2008","unstructured":"White, D. E. & Burchill, S. A. BAY 11-7082 induces cell death through NF-kappaB-independent mechanisms in the Ewing\u2019s sarcoma family of tumours. Cancer Lett. 268, 212\u2013224 (2008).","journal-title":"Cancer Lett."},{"key":"5506_CR58","first-page":"416036","volume":"2012","author":"J Lee","year":"2012","unstructured":"Lee, J., Rhee, M. H., Kim, E. & Cho, J. Y. BAY 11-7082 is a broad-spectrum inhibitor with anti-inflammatory activity against multiple targets. Mediat. Inflamm. 2012, 416036 (2012).","journal-title":"Mediat. Inflamm."},{"key":"5506_CR59","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1084\/jem.191.8.1281","volume":"191","author":"RJ Grumont","year":"2000","unstructured":"Grumont, R. J. & Gerondakis, S. Rel induces interferon regulatory factor 4 (IRF-4) expression in lymphocytes: modulation of interferon-regulated gene expression by rel\/nuclear factor kappaB. J. Exp. Med. 191, 1281\u20131292 (2000).","journal-title":"J. Exp. Med."},{"key":"5506_CR60","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1128\/MCB.20.8.2687-2695.2000","volume":"20","author":"C Chen","year":"2000","unstructured":"Chen, C., Edelstein, L. C. & Gelinas, C. The Rel\/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol. Cell Biol. 20, 2687\u20132695 (2000).","journal-title":"Mol. Cell. Biol."},{"key":"5506_CR61","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1038\/ncb1980","volume":"11","author":"JS Lee","year":"2009","unstructured":"Lee, J. S. et al. FLIP-mediated autophagy regulation in cell death control. Nat. Cell Biol. 11, 1355\u20131362 (2009).","journal-title":"Nat. Cell Biol."},{"key":"5506_CR62","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.4161\/cc.6.18.4730","volume":"6","author":"G Sarek","year":"2007","unstructured":"Sarek, G. & Ojala, P. M. p53 reactivation kills KSHV lymphomas efficiently in vitro and in vivo: new hope for treating aggressive viral lymphomas. Cell Cycle 6, 2205\u20132209 (2007).","journal-title":"Cell Cycle"},{"key":"5506_CR63","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1097\/QAD.0000000000001567","volume":"31","author":"PH Goncalves","year":"2017","unstructured":"Goncalves, P. H., Uldrick, T. S. & Yarchoan, R. HIV-associated Kaposi sarcoma and related diseases. AIDS 31, 1903\u20131916 (2017).","journal-title":"AIDS"},{"key":"5506_CR64","doi-asserted-by":"publisher","unstructured":"Patil, A., Manzano, M. & Gottwein, E. CK1\u03b1 and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma. Blood https:\/\/doi.org\/10.1182\/blood-2018-01-828418 (2018).","DOI":"10.1182\/blood-2018-01-828418"},{"key":"5506_CR65","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.1247005","volume":"343","author":"O Shalem","year":"2014","unstructured":"Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84\u201387 (2014).","journal-title":"Science"},{"key":"5506_CR66","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/nbt.2647","volume":"31","author":"PD Hsu","year":"2013","unstructured":"Hsu, P. D. et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat. Biotechnol. 31, 827\u2013832 (2013).","journal-title":"Nat. Biotechnol."},{"key":"5506_CR67","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.cell.2015.02.038","volume":"160","author":"S Chen","year":"2015","unstructured":"Chen, S. et al. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell 160, 1246\u20131260 (2015).","journal-title":"Cell"},{"key":"5506_CR68","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","volume":"171","author":"A Reddy","year":"2017","unstructured":"Reddy, A. et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell 171, 481\u2013494 (2017).","journal-title":"Cell"},{"key":"5506_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"5506_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v025.i01","volume":"25","author":"S Le","year":"2008","unstructured":"Le, S., Josse, J. & Husson, F. FactoMineR: an R package for multivariate analysis. J. Stat. Softw. 25, 1\u201318 (2008).","journal-title":"J. Stat. Softw."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-05506-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-05506-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-05506-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T16:45:19Z","timestamp":1671554719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-05506-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,15]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["5506"],"URL":"https:\/\/doi.org\/10.1038\/s41467-018-05506-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,15]]},"assertion":[{"value":"4 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3263"}}